In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sagent Pharmaceuticals nets $98.4mm through its IPO

Executive Summary

Sagent Pharmaceuticals Inc. (generic injectable drugs) has netted $98.4mm through its initial public offering of 6.6mm common shares (including the overallotment) at $16 each, the high end of its proposed $14-16 range. The company also sold more stock than it planned--it was gearing towards only 5mm shares.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies